Brian Tyler Sells 8,463 Shares of McKesson (NYSE:MCK) Stock

McKesson Corporation (NYSE:MCK) CEO Brian Tyler sold 8,463 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the completion of the sale, the chief executive officer owned 5,919 shares in the company, valued at approximately $4,697,081.64. This trade represents a 58.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

McKesson Trading Down 3.1%

Shares of NYSE MCK opened at $793.32 on Friday. McKesson Corporation has a twelve month low of $637.00 and a twelve month high of $999.00. The company has a market capitalization of $92.88 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 1.35 and a beta of 0.31. The firm has a 50-day moving average of $766.72 and a two-hundred day moving average of $838.77.

McKesson (NYSE:MCK) last issued its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The firm had revenue of $96.30 billion during the quarter, compared to analysts’ expectations of $101.35 billion. During the same period last year, the firm posted $10.12 earnings per share. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, research analysts predict that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is currently 8.53%.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson’s last earnings report beat adjusted EPS estimates and management reaffirmed FY2027 adjusted EPS guidance of $43.80 to $44.60, which supports the company’s longer-term earnings outlook.
• Positive Sentiment: Analyst sentiment remains generally favorable, with a moderate buy consensus and multiple firms maintaining overweight/buy ratings, suggesting Wall Street still sees upside potential.
• Neutral Sentiment: McKesson recently announced its next earnings date for August 5, so investors are likely in a wait-and-see mode ahead of the next quarterly update.
• Neutral Sentiment: The company also disclosed new debt tied to the planned separation of its Medical-Surgical Solutions business, a move that may improve strategic focus but also keeps attention on execution and balance-sheet changes.
• Negative Sentiment: Investors are still reacting to the prior quarter’s revenue shortfall, which outweighed the EPS beat and has kept sentiment cautious around near-term growth.
• Negative Sentiment: Recent leadership turnover, including the planned retirement of Chief Strategy and Business Development Officer Thomas L. Rodgers and a large CEO stock sale under a 10b5-1 plan, may be adding to concerns about insider confidence and continuity.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. UBS Group increased their price objective on McKesson from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wells Fargo & Company decreased their price objective on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. William Blair began coverage on McKesson in a research report on Tuesday, April 28th. They set an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $875.00 price target on shares of McKesson in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $960.53.

Institutional Investors Weigh In On McKesson

Large investors have recently made changes to their positions in the company. University of Texas Texas AM Investment Management Co. bought a new stake in McKesson during the fourth quarter worth about $25,000. Swiss RE Ltd. acquired a new stake in shares of McKesson in the 4th quarter valued at $26,000. State of Wyoming acquired a new stake in McKesson in the second quarter worth about $29,000. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of McKesson during the 3rd quarter worth approximately $33,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of McKesson during the 4th quarter worth approximately $33,000. Institutional investors own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.